Nebenwirkungen · Erbitux
Erbitux 5 mg/mL solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-113179 · Präparat HOS-093871
Skin reactions Skin reactions may develop in more than 80% of patients and mainly present as acne-like rash and/or, less frequently, as pruritus, dry skin, desquamation, hypertrichosis, or nail disorders (e.g. paronychia). Approximately 15% of the skin reactions are severe, including single cases of skin necrosis. The majority of skin reactions develop within the first three weeks of therapy. They generally resolve, without sequelae, over time following cessation of treatment if the recommended adjustments in dose regimen are followed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T11:55:00Z · SHA-256 073f5effd93351048ad74afee3f940b1c0ad5d24722452304a7b761a65e30f20 · Passage bfa1f92728e432f27d0106e1401c3f5d1ae50c0c5324bb1cc7dfa8bcdc9e5bd6 · Zeichen 11795–12354 im Abschnitt